Tissue Eng Regen Med.  2020 Oct;17(5):683-693. 10.1007/s13770-020-00276-2.

Erythropoietin-Modified Mesenchymal Stem Cells Enhance Antifibrosis Efficacy in Mouse Liver Fibrosis Model

• Wang X
• Wang H
• Lu J
• Feng Z
• Liu Z
• Song H
• Wang H
• Zhou Y
• Xu J

• KMID: 2507324
• DOI: http://doi.org/10.1007/s13770-020-00276-2

Abstract

BACKGROUND
Mesenchymal stem cell (MSC)-based cell transplantation is an effective means of treating chronic liver injury, fibrosis and end-stage liver disease. However, extensive studies have found that only a small number of transplanted cells migrate to the site of injury or lesion, and repair efficacy is very limited.
METHODS
Bone marrow-derived MSCs (BM-MSCs) were generated that overexpressed the erythropoietin (EPO) gene using a lentivirus. Cell Counting Kit-8 was used to detect the viability of BM-MSCs after overexpressing EPO. Cell migration and apoptosis were verified using Boyden chamber and flow cytometry, respectively. Finally, the anti-fibrosis efficacy of EPO-MSCs was evaluated in vivo using immunohistochemical analysis.
RESULTS
EPO overexpression promoted cell viability and migration of BM-MSCs without inducing apoptosis, and EPO-MSC treatment significantly alleviated liver fibrosis in a carbon tetrachloride (CCl₄ ) induced mouse liver fibrosis model.
CONCLUSION
EPO-MSCs enhance anti-fibrotic efficacy, with higher cell viability and stronger migration ability compared with treatment with BM-MSCs only. These findings support improving the efficiency of MSCs transplantation as a potential therapeutic strategy for liver fibrosis.

Keyword

BM-MSCs; Erythropoietin; Migration; Anti-fibrosis efficacy; Liver fibrosis